Many meetings are siloed by modality (CAR T or TCEs or mAbs). This summit is purpose-built to cross-pollinate across modalities and disease areas so that attendees leave with a complete translational picture for immune reset.
Program highlights include Kite Pharma, Bristol Myers Squibb, Cullinan Therapeutics, FAU Erlangen–Nürnberg, aand others, spanning mechanism, clinical operations, and combination strategies.
With 50+ leading innovators and sessions on trial “windows of opportunity,” CNS translation, and defining optimal B cell depletion across tissues, you’ll access the current frontier rather than a single track view.
Timed to the Market Inflection
The field is surging now: investors and pharma are backing immune reset strategies from CAR T to bispecifics. A 2025 analysis tallies 80+ candidates in development across 380+ trials, framing a true race to reset autoimmunity.
On the biologics side, 2025 has been called “the year of the bispecific”, with multispecific antibodies rising across oncology and expanding into autoimmunity; dealmaking remains robust even as overall transactions slowed.
Recent deals and pipeline moves, including Cullinan’s $700M BCMA TCE pairing strategy and Ouro Medicines’ $120M launch to develop BCMA and other TCEs for lupus and scleroderma, signal a strong and lasting industry commitment to immune reset.
Practical Takeaways You Won’t Get Elsewhere
- Mechanisms to operations: From deep tissue Bcell clearance evidence to trial design discussion regimens), sessions translate science into actionable protocols
- Beyond B cells: See where T cell targeting and tolerance restoration fit, including emerging precision T cell platforms from companies like Marengo Therapeutics in autoimmunity.
- Neurology focus: MS case studies and reviews clarify how B cell depletion reshapes immune networks which is key for CNS translation and biomarker strategies.
Who You’ll Meet (and Why It Matters)
The speaker faculty includes KOLs and decision makers driving immune reset strategies in biopharma and academia, which is precisely the people shaping next wave trials, partnerships, and tool adoption.
For solution providers (sequencing, profiling, CROs), this audience actively seeks tools for complex immune biology, B cell repertoire characterization, and faster Phase I pathways.
Explore the Full Event Guide
- 50+ Industry Attendees
- 18+ World-Class Speakers
- 5+ Modalities Covered
- 6+ Hours of Unrivaled Networking Opportunities
- 2 Deep-Dive Workshops
- The only industry forum dedicated to advancing curative therapies for autoimmune diseases through immune resetting
Explore the Brand-New Agenda
Hear the latest industry breakthroughs in B-cell mechanistic understanding and gain exclusive modality and platform insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself as the go-to service provider of the rapidly progressing ‘Immune Resetting’ landscape to ensure your brand is at the heart of deals in this evolving space.
Join Biopharma Experts
Be part of the most critical conversations shaping the future of autoimmune therapy. Connect with like-minded experts across every stage of drug development, from discovery to clinical application, and dive into focused discussions on redefining immune reset.